Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

Conditions

Autoimmune Diseases, Chronic Inflammatory Rheumatism, Sars-CoV2

Keywords

Covid-19, chronic inflammatory rheumatism, auto-immune diseases, auto-inflammatory diseases, intensive care unit

Brief summary

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

Perrot L, Boyer L, Flipo RM, Marotte H, Pertuiset E, Miceli C, Thomas T, Seror R, Chazerain P, Roux N, Richez C, Pham T, FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium.

2023-07-051 citations

10.1016/j.jbspin.2023.105608

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort

Marie‐Elise Truchetet, Élodie Drumez, Thomas Barnetche, Claire Martin, Mathilde Devaux et al. (12 authors)

RMD Open2022-09-012 citations

10.1136/rmdopen-2022-002476

COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study.

Vieira M, Comarmond C, Labreuche J, Mirouse A, Saadoun D, Richez C, Flipo RM, Hachulla E, Drumez E, Cacoub P, FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors.

2022-07-207 citations

10.1016/j.jaut.2022.102868

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.

Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C, FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors, FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors.

2021-03-25215 citations

10.1016/s2665-9913(21)00059-x

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Florence A. Aeschlimann

Annals of the Rheumatic Diseases2020-12-02201 citations

10.1136/annrheumdis-2020-218310

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* All patients, children and adults * Patients with known chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases with proven/suspected SARS-Cov-2 infection (COVID-19) (by biological data (serological or positive Cov-2 PCR) or CT scan images or clinical observations consistent with covid-19)

Exclusion criteria

* patients opposed to the use of their data * patients under guardianship, protected persons

Design outcomes

Primary

Measure	Time frame
Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death	From Baseline up to Day 21 after first symptoms of covid-19

Secondary

Measure	Time frame
Proportion of patients who die from a severe form of covid-19	From Baseline up to Day 21 after first symptoms of covid-19
Proportion of patients who present an history of diabetes according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)	At the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of Asthma according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of Hypertension according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of cardiac disease according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of stroke according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)
Proportion of patients who present an history of cancer according to medical records	Before the set-up of first symptoms of covid-19 (Baseline visit)

Countries

France

Contacts

PRINCIPAL_INVESTIGATOREric Hachulla, MD,PhD

University Hospital, Lille

Outcome results